RxDoctor Payments Data

Giancarlo Cortez, PA

Physician Assistant · Jersey City, NJNPI 1457035362

Payments from drug & device makers

$1,393in general payments, 2019–2025

Across 36 payments — averaging $38.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$862
  • Boston Scientific$170
  • GSK$98
  • AstraZeneca$75
  • Novo Nordisk$56
  • Bayer$39
  • plus $93 from 5 others

What the payments were for

  • Food & beverage$1,393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,393 in reported general payments places this provider in the 80th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$28,297
Medicare patients
78
Services billed
403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$114,281
JardianceEmpagliflozin71$65,811
LinzessLinaclotide75$47,875
JanuviaSitagliptin Phosphate32$31,979
JanumetSitagliptin Phos/Metformin Hcl32$31,226
RybelsusSemaglutide19$30,183
Diclofenac Sodium117$27,464
EliquisApixaban24$22,660
VascepaIcosapent Ethyl45$21,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$20,814
MounjaroTirzepatide17$17,751
FarxigaDapagliflozin Propanediol24$17,156
Atrovent HfaIpratropium Bromide16$6,925
Omega-3 Acid Ethyl Esters37$4,448
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl30$3,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$56$144,464106 claims
Boehringer IngelheimJardiance$862$65,81171 claims
PfizerEliquis$18$22,66024 claims
GSKTrelegy Ellipta$98$20,81433 claims
AstraZenecaFarxiga$75$17,15624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →